Chemical Structure : FX1
CAS No.: 1426138-42-2
货号: PC-60927Not For Human Use, Lab Use Only.
FX1 (BCL6 inhibitor FX1) is a potent, specific BCL6 BTB domain inhibitor with Kd of 7 uM, binds with a greater affinity than the natural BCL6 ligand SMRT (Kd=30 uM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | ¥980 | In stock | |
25 mg | ¥1580 | In stock | |
50 mg | ¥2480 | In stock | |
100 mg | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
FX1 (BCL6 inhibitor FX1) is a potent, specific BCL6 BTB domain inhibitor with Kd of 7 uM, binds with a greater affinity than the natural BCL6 ligand SMRT (Kd=30 uM).
FX1 exhibits 10-fold greater inhibitory activity against the BCL6 BTB domain in reporter assays with IC50 of 35 uM, displays good selectivity against a panel of 50 different kinases.
FX1 disrupts formation of the BCL6 repression complex, reactivates BCL6 target genes, suppresses ABC-DLBCL cells in vitro and in vivo, as well as primary human ABC-DLBCL specimens ex vivo.
分子量 | 368.806 | |
分子式 | C14H9ClN2O4S2 | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mg/mL in DMSO |
|
Chemical Name/SMILES |
(Z)-3-(5-(5-chloro-2-oxoindolin-3-ylidene)-4-oxo-2-thioxothiazolidin-3-yl)propanoic acid |
1. Cardenas MG, et al. J Clin Invest. 2016 Sep 1;126(9):3351-62.
2. Deb D, et al. Cancer Res. 2017 Jun 1;77(11):3070-3081.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright